Načítá se...
The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
Ibrutinib, the first in class of the oral covalent Bruton tyrosine kinase (BTK) inhibitors, has profoundly changed the treatment landscape of chronic lymphocytic leukemia (CLL). The phase III RESONATE and RESONATE-2 trials first demonstrated the superiority of ibrutinib over ofatumumab in the relaps...
Uloženo v:
| Vydáno v: | Ther Adv Hematol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970705/ https://ncbi.nlm.nih.gov/pubmed/33796237 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620721989588 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|